Trial · NCT01589302
Results by group62
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 62
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL. | Treatment (Ibrutinib) | All patients | 64 | 95% Confidence Interval 57 to 72 | percentage of patients |
| Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL. | Treatment (Ibrutinib) | Del(17p) | 64 | 95% Confidence Interval 54 to 75 | percentage of patients |
| Determine the 2 Year Progression-free Survival (PFS) of Single Agent PCI-32765 in Patients With Relapsed and Refractory CLL. | Treatment (Ibrutinib) | non-Del(17p) | 64 | 95% Confidence Interval 54 to 75 | percentage of patients |
| Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines | Treatment (Ibrutinib) | All patients | 63 | 95% Confidence Interval 55 to 70 | percentage of patients |
| Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines | Treatment (Ibrutinib) | Del(17p) | 66 | 95% Confidence Interval 55 to 76 | percentage of patients |
| Best Overall Response Rate Using the Revised International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Working Group Guidelines | Treatment (Ibrutinib) | non-Del(17p) | 59 | 95% Confidence Interval 48 to 70 | percentage of patients |
| Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients | Treatment (Ibrutinib) | All patients | 63 | 95% Confidence Interval 55 to 70 | patients |
| Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients | Treatment (Ibrutinib) | Del(17p) | 66 | 95% Confidence Interval 55 to 76 | patients |
| Number of Patients With 6 Month ORR of Single Agent Ibrutinib in Relapsed and Refractory CLL Patients | Treatment (Ibrutinib) | Non-del(17p) | 59 | 95% Confidence Interval 48 to 70 | patients |
| Percentage of Patients With Overall Survival (OS) | Treatment (Ibrutinib) | All patients | 78 | 95% Confidence Interval 71 to 84 | percent of patients |
| Percentage of Patients With Overall Survival (OS) | Treatment (Ibrutinib) | Del(17p) | 75 | 95% Confidence Interval 63 to 83 | percent of patients |
| Percentage of Patients With Overall Survival (OS) | Treatment (Ibrutinib) | non-Del(17p) | 81 | 95% Confidence Interval 71 to 89 | percent of patients |
| 2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765 | Treatment (Ibrutinib) | All patients | 69 | 95% Confidence Interval 61 to 76 | percent of patients |
| 2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765 | Treatment (Ibrutinib) | Del(17p) | 66 | 95% Confidence Interval 54 to 76 | percent of patients |
| 2-year Kaplan-Meier Estimate of OS for Relapsed and Refractory CLL Patients Treated With Single Agent PCI-32765 | Treatment (Ibrutinib) | non-Del(17p) | 72 | 95% Confidence Interval 60 to 81 | percent of patients |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Anemia | 13 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Febrible Neutropenia | 2 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Leukocytosis | 18 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Atrial Fibrillation | 1 | patients | |
| Number of Patients With Adverse Events, Graded According to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | Treatment (Ibrutinib) | Diarrhea | 2 | patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01589302/results